Outlook Therapeutics, Inc. (NASDAQ:OTLK) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Outlook Therapeutics, Inc. (NASDAQ:OTLK) have received an average recommendation of “Moderate Buy” from the six ratings firms that are presently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $27.40.

A number of research firms have issued reports on OTLK. HC Wainwright restated a “buy” rating and set a $30.00 price objective on shares of Outlook Therapeutics in a research note on Friday, January 17th. Chardan Capital reaffirmed a “neutral” rating on shares of Outlook Therapeutics in a report on Monday, December 2nd. Guggenheim reaffirmed a “buy” rating and set a $12.00 price target on shares of Outlook Therapeutics in a research report on Friday, January 17th. Finally, BTIG Research decreased their price objective on Outlook Therapeutics from $50.00 to $9.00 and set a “buy” rating for the company in a report on Friday, November 29th.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Rhumbline Advisers increased its stake in shares of Outlook Therapeutics by 1,329.6% in the 4th quarter. Rhumbline Advisers now owns 188,050 shares of the company’s stock valued at $355,000 after purchasing an additional 174,896 shares in the last quarter. Geode Capital Management LLC grew its holdings in Outlook Therapeutics by 49.2% in the third quarter. Geode Capital Management LLC now owns 341,959 shares of the company’s stock valued at $1,826,000 after purchasing an additional 112,812 shares during the period. XTX Topco Ltd purchased a new stake in shares of Outlook Therapeutics in the third quarter valued at approximately $199,000. Squarepoint Ops LLC acquired a new position in shares of Outlook Therapeutics during the 2nd quarter worth approximately $232,000. Finally, State Street Corp lifted its position in shares of Outlook Therapeutics by 10.0% during the 3rd quarter. State Street Corp now owns 232,542 shares of the company’s stock valued at $1,242,000 after buying an additional 21,201 shares in the last quarter. Institutional investors and hedge funds own 11.20% of the company’s stock.

Outlook Therapeutics Price Performance

NASDAQ OTLK opened at $1.73 on Friday. The company has a market cap of $55.33 million, a price-to-earnings ratio of -0.19 and a beta of 0.58. The stock’s fifty day moving average price is $1.88 and its 200 day moving average price is $4.79. Outlook Therapeutics has a 1 year low of $0.87 and a 1 year high of $12.85.

Outlook Therapeutics (NASDAQ:OTLK) last announced its quarterly earnings data on Friday, December 27th. The company reported ($0.77) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.83) by $0.06. Research analysts expect that Outlook Therapeutics will post -2.25 earnings per share for the current year.

Outlook Therapeutics Company Profile

Outlook Therapeutics, Inc, operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases.